Literature DB >> 24900871

2-(2-Arylphenyl)benzoxazole As a Novel Anti-Inflammatory Scaffold: Synthesis and Biological Evaluation.

Kapileswar Seth1, Sanjeev K Garg1, Raj Kumar1, Priyank Purohit1, Vachan S Meena1, Rohit Goyal2, Uttam C Banerjee1, Asit K Chakraborti1.   

Abstract

The 2-(2-arylphenyl)benzoxazole moiety has been found to be a new and selective ligand for the enzyme cyclooxygenase-2 (COX-2). The 2-(2-arylphenyl)benzoxazoles 3a-m have been synthesized by Suzuki reaction of 2-(2-bromophenyl)benzoxazole. Further synthetic manipulation of 3f and 3i led to 3o and 3n, respectively. The compounds 3g, 3n, and 3o selectively inhibited COX-2 with selectivity index of 3n much better than that of the COX-2 selective NSAID celecoxib. The in vivo anti-inflammatory potency of 3g and 3n is comparable to that of celecoxib and the nonselective NSAID diclofenac at two different doses, and 3o showed better potency compared to these clinically used NSAIDs.

Entities:  

Keywords:  2-(2-Arylphenyl)benzoxazoles; 3D QSAR; cyclooxygenase-2 selective; in vivo potency; novel anti-inflammatory scaffold

Year:  2014        PMID: 24900871      PMCID: PMC4027739          DOI: 10.1021/ml400500e

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  28 in total

Review 1.  Structural and functional basis of cyclooxygenase inhibition.

Authors:  Anna L Blobaum; Lawrence J Marnett
Journal:  J Med Chem       Date:  2007-03-07       Impact factor: 7.446

2.  Differential cyclooxygenase-2 enzyme expression in radiosensitive versus radioresistant glioblastoma multiforme cell lines.

Authors:  Aftab Karim; Kevin McCarthy; Ajay Jawahar; Donald Smith; Brian Willis; Anil Nanda
Journal:  Anticancer Res       Date:  2005 Jan-Feb       Impact factor: 2.480

Review 3.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

Authors:  R A Gupta; R N Dubois
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

Review 4.  Classification of scaffold-hopping approaches.

Authors:  Hongmao Sun; Gregory Tawa; Anders Wallqvist
Journal:  Drug Discov Today       Date:  2011-10-26       Impact factor: 7.851

Review 5.  Cancer prevention: a new era beyond cyclooxygenase-2.

Authors:  Basil Rigas; Khosrow Kashfi
Journal:  J Pharmacol Exp Ther       Date:  2005-04-01       Impact factor: 4.030

6.  Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.

Authors:  Khong Bee Kang; Ting Ting Wang; Chow Thai Woon; Elizabeth S Cheah; Xiao Lei Moore; Congju Zhu; Meng Cheong Wong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-03-01       Impact factor: 7.038

7.  Fatal allergic vasculitis associated with celecoxib.

Authors:  F Schneider; F Meziani; C Chartier; M Alt; A Jaeger
Journal:  Lancet       Date:  2002-03-09       Impact factor: 79.321

8.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

Authors:  J L Masferrer; B S Zweifel; P T Manning; S D Hauser; K M Leahy; W G Smith; P C Isakson; K Seibert
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

9.  Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells.

Authors:  Irene V Bijnsdorp; Jaap van den Berg; Gitta K Kuipers; Laurine E Wedekind; Ben J Slotman; Johannes van Rijn; M Vincent M Lafleur; Peter Sminia
Journal:  J Neurooncol       Date:  2007-04-20       Impact factor: 4.130

Review 10.  Why do people with rheumatoid arthritis still die prematurely?

Authors:  S E Gabriel
Journal:  Ann Rheum Dis       Date:  2008-12       Impact factor: 19.103

View more
  8 in total

1.  Design, synthesis, molecular modeling and biological evaluation of novel Benzoxazole-Benzamide conjugates via a 2-Thioacetamido linker as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers.

Authors:  Ibrahim H Eissa; Radwan El-Haggar; Mohammed A Dahab; Marwa F Ahmed; Hazem A Mahdy; Reem I Alsantali; Alaa Elwan; Nicolas Masurier; Samar S Fatahala
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

2.  High-throughput screens for agonists of bone morphogenetic protein (BMP) signaling identify potent benzoxazole compounds.

Authors:  Shayna T J Bradford; Egon J Ranghini; Edward Grimley; Pil H Lee; Gregory R Dressler
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

3.  Room-temperature palladium-catalyzed direct 2-arylation of benzoxazoles with aryl and heteroaryl bromides.

Authors:  Feng Gao; Byeong-Seon Kim; Patrick J Walsh
Journal:  Chem Commun (Camb)       Date:  2014-07-31       Impact factor: 6.222

4.  Bimetallic Cooperative Catalysis for Decarbonylative Heteroarylation of Carboxylic Acids via C-O/C-H Coupling.

Authors:  Chengwei Liu; Chong-Lei Ji; Tongliang Zhou; Xin Hong; Michal Szostak
Journal:  Angew Chem Int Ed Engl       Date:  2021-04-06       Impact factor: 15.336

5.  Molecular modeling, synthesis, characterization and pharmacological evaluation of benzo[d]oxazole derivatives as non-steroidal anti-inflammatory agents.

Authors:  Ashok K Shakya; Avneet Kaur; Belal O Al-Najjar; Rajashri R Naik
Journal:  Saudi Pharm J       Date:  2015-03-25       Impact factor: 4.330

6.  Novel benzoxazole derivatives DCPAB and HPAB attenuate Th1 cell-mediated inflammation through T-bet suppression.

Authors:  Yeon Ji Oh; Darong Kim; Sera Oh; Eun Jung Jang; Hee Yeon Won; Hana Jeong; Mi Gyeong Jeong; Hea-Young Park Choo; Eun Sook Hwang
Journal:  Sci Rep       Date:  2017-02-07       Impact factor: 4.379

7.  Deep eutectic solvent-catalyzed arylation of benzoxazoles with aromatic aldehydes.

Authors:  Phuong Hoang Tran; Anh-Hung Thi Hang
Journal:  RSC Adv       Date:  2018-03-20       Impact factor: 4.036

8.  Biological activity of 3-(2-benzoxazol-5-yl)alanine derivatives.

Authors:  Katarzyna Guzow; Ewa Mulkiewicz; Michał Obuchowski; Wiesław Wiczk
Journal:  Amino Acids       Date:  2021-07-08       Impact factor: 3.520

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.